Open AccessApplication of neoadjuvant chemotherapy combined with anlotinib in occult breast cancer: A case report and review of literature
Author(s) -
Yu Zhang,
Di Wu,
Bo Zhao,
Xueliang Tian,
Tiancheng Yao,
Feng Li,
Wei-fang Liu,
Aiping Shi
Publication year - 2021
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v9.i4.919
Subject(s) - medicine , breast cancer , neoadjuvant therapy , cytokeratin , axillary lymph node dissection , axillary lymph nodes , chemotherapy , oncology , lymph node , sentinel lymph node , cancer , pathology , immunohistochemistry
Occult breast cancer (OBC) is a special type of breast cancer presenting as axillary lymph node metastasis with undetectable primary lesions in the breast. Due to its low incidence and unique clinical manifestations, there is a lack of consensus on the diagnosis and treatment of OBC. We report a case of OBC treated with neoadjuvant chemotherapy combined with anlotinib. The treatment was well tolerated, and the patient achieved a pathologic complete response.